🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Intestinal Neuroendocrine Tumor

Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour NCT06876532NA10 sites📍 Angers📍 Bordeaux📍 Caen Institut Claudius Regaud · Tests: Additional blood tests (CRP and serum albumin) and data collection. Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET NCT04954820Phase 228 sites📍 Angers📍 Bordeaux📍 Brest Institut du Cancer de Montpellier - Val d'Aurelle · Tests: Lutathera A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort NCT07808164n/a2 sites📍 Hanoi📍 Ho Chi Minh City Tam Anh Research Institute · Tests: IHC analysis for ENPP1, cGAS, and FAP expression DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. NCT06337760n/a1 site📍 Milan European Institute of Oncology START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. Evaluation for NCI Surgery Branch Clinical Research Protocols NCT00001823n/a1 site📍 Bethesda National Cancer Institute (NCI) EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors NCT06624865n/a1 site📍 Lyon Hospices Civils de Lyon · Tests: Blood and stool sampling GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Pancreas Registry and High Risk Registry NCT02775461n/a2 sites📍 New York📍 New York Icahn School of Medicine at Mount Sinai Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) NCT04498767NA13 sites📍 Anderlecht📍 Ghent📍 Wilrijk European Organisation for Research and Treatment of Cancer … · Tests: Stereotactic body radiotherapy, Palliative RT A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors NCT07317505Phase 13 sites📍 Huntersville📍 Dallas📍 Fairfax Conjupro Biotherapeutics, Inc. · Tests: JMT108 FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis NCT06206707NA1 site📍 Aarhus N University of Aarhus · Tests: Faecal Microbiota Transplantation (FMT), Placebo Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients NCT04038619Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Fecal Microbiota Transplantation, Loperamide Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. NCT07686835Phase 22 sites📍 Nijmegen📍 Groningen Radboud University Medical Center · Tests: Dried chicory roots, Placebo Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908Phase 22 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites📍 Duarte📍 Glendale📍 La Jolla Turning Point Therapeutics, Inc. · Tests: Oral repotrectinib (TPX-0005) Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy NCT07635732n/a1 site📍 Gratwein Medical University of Graz Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study NCT05645510n/a1 site📍 Edmonton University of Alberta Genomic Investigation of Unusual Responders NCT03740503n/a1 site📍 Toronto University Health Network, Toronto Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases NCT02185443Phase 21 site📍 São Paulo University of Sao Paulo · Tests: SBRT
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy